BALOXAVIR

/static/temp/default.svg

Search structure


Synonyms	Baloxavir S-033447
Status
Molecule Category	UNKNOWN
UNII	4G86Y4JT3F


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	FIDLLEYNNRGVFR-CTNGQTDRSA-N
Smiles	O=C1c2c(O)c(=O)ccn2N([C@@H]2c3ccccc3SCc3c2ccc(F)c3F)[C@@H]2COCCN12
InChI	InChI=1S/C24H19F2N3O4S/c25-16-6-5-13-15(20(16)26)12-34-18-4-2-1-3-14(18)21(13)29-19-11-33-10-9-27(19)24(32)22-23(31)17(30)7-8-28(22)29/h1-8,19,21,31H,9-12H2/t19-,21+/m1/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C24H19F2N3O4S
Molecular Weight	483.5
AlogP	2.98
Hydrogen Bond Acceptor	7.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	1.0
Polar Surface Area	75.01
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	34.0

Bioactivity

Mechanism of Action	Action	Reference
Polymerase acidic protein inhibitor	INHIBITOR	FDA FDA PubMed

Assay Description	Organism	Bioactivity	Reference
Inhibition of CEN polymerase activity in Influenza A/California/04/2009 (H1N1)pdm09 NP/PA/PB1/PB2 complex transfected in HEK293T cells co-expressing beta-galactosidase at 100 nM preincubated for 3 hrs followed by viral gene transfection and measured after 24 hrs by ONPG substrate based luciferase reporter gene mini-replicon assay relative to control	Influenza A virus (A/California/04/2009(H1N1))	99.7 %
Inhibition of CEN polymerase activity in Influenza A/California/04/2009 (H1N1)pdm09 NP/PA/PB1/PB2 complex transfected in HEK293T cells co-expressing beta-galactosidase at 25 nM preincubated for 3 hrs followed by viral gene transfection and measured after 24 hrs by ONPG substrate based luciferase reporter gene mini-replicon assay relative to control	Influenza A virus (A/California/04/2009(H1N1))	99.6 %
Antiviral activity against Influenza A/California/04/2009 (H1N1)pdm09 infected in MDCK cells assessed as protection against virus-induced cell death by CellTiter-Glo assay	Influenza A virus	0.9 nM
Inhibition of biotinylated 5-(4-((Z)-3-Carboxy-3-hydroxyacryloyl)-4-(4-chlorobenzyl)piperidine-1-carbonyl)-2-((13,35-dioxo-39-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazole-4-yl)-3,6,9,16,19,22,25,28,31-nonaoxa-12,34-diazanonatriacontyl)oxy)benzoic acid binding to Influenza A virus (A/California/07/2009(H1N1)) N-terminal GST-tagged polymerase acidic subunit N-terminal domain expressed in Escherichia coli BL21 (DE3) RIL cells measured after 120 mins by Alphascreen assay	Influenza A virus (A/California/07/2009(H1N1))	24.0 nM
Antiviral activity against Influenza A virus A/WSN/33(H1N1) strain infected in MDCK cells assessed as reduction in viral infection incubated for 48 hrs by crystal violet staining based assay	influenza A virus	3.0 nM
Antiviral activity against Influenza A virus A/Puerto Rico/8/34(H1N1) strain infected in MDCK cells assessed as reduction in viral infection incubated for 48 hrs by crystal violet staining based assay	influenza A virus	7.0 nM
Antiviral activity against Influenza A virus A/Virginia/ATCC2/2009(H1N1) strain infected in MDCK cells assessed as reduction in viral infection incubated for 48 hrs by crystal violet staining based assay	influenza A virus	6.0 nM
Antiviral activity against Influenza A virus A/California/7/2009(H1N1) strain infected in MDCK cells assessed as reduction in viral infection incubated for 48 hrs by crystal violet staining based assay	influenza A virus	4.0 nM
Antiviral activity against Influenza A virus A/Aichi/8/68(H3N2) strain infected in MDCK cells assessed as reduction in viral infection incubated for 48 hrs by crystal violet staining based assay	influenza A virus	4.0 nM
Antiviral activity against Influenza A virus B/Lee/40(type B) strain infected in MDCK cells assessed as reduction in viral infection incubated for 48 hrs by crystal violet staining based assay	influenza A virus	170.0 nM

Related Entries

Cross References

Resources	Reference
ChEMBL	CHEMBL4297215
DrugBank	DB15675
FDA SRS	4G86Y4JT3F
PDB	E4Z
PubChem	124081876
SureChEMBL	SCHEMBL20101933

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).